Analytical Data
-
基因名
CSNK1G2
-
简介
Casein kinase I gamma-2 is a serine/threonine protein kinase that targets acidic proteins and phosphorylates a variety of substrates, such as COL4A3BP/CERT, MTA1 and SMAD3, especially destabilizing SMAD3 and inhibiting TGF- beta reaction. Hyperphosphorylation of COL4A3BP/CERT disrupts ER-to-Golgi transport and affects the synthesis of ceramide and sphingomyelin. CSNK1G2 Protein, Human (sf9, GST) is the recombinant human-derived CSNK1G2, expressed by Sf9 insect cells, with GST labeled tag. The total length of CSNK1G2 Protein, Human (sf9, GST) is 414 a.a..
- Application
-
别名
CSNK1G2; casein kinase 1 gamma 2; CK1g2
-
种属
Human
-
表达系统
Baculovirus
-
标签
GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P78368
-
表达区间
D2-K415
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CSNK1G2, or Casein Kinase 1 Gamma 2, is a member of the casein kinase 1 (CK1) family, which is involved in various cellular processes including the regulation of circadian rhythms, Wnt signaling, and the cell cycle. Due to its critical role in these pathways, abnormalities in CSNK1G2 activity are implicated in several pathological conditions, such as cancer and neurodegenerative disorders. Recently, research has focused on the structural and functional characterization of CSNK1G2 to understand its mechanisms of action at the molecular level. Recombinant CSNK1G2 protein has been produced to facilitate in vitro studies, enabling researchers to analyze its enzymatic activity, substrate specificity, and interaction with regulatory proteins. This has proven essential for deciphering the intricate regulatory networks in which CSNK1G2 is involved, potentially leading to the identification of novel therapeutic targets. The generation of high-quality recombinant CSNK1G2 protein lays the foundation for further functional assays and structure-based drug design, aiming to modulate its activity in disease contexts. Insights gained from these studies could contribute to the development of targeted therapies, providing promising avenues for the treatment of diseases associated with CK1 dysfunction.
